Study of the Efficacy and Safety of Inhaled Technosphere Insulin in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus Clinical Trial

Official title:

Efficacy and Safety of Inhaled Technosphere Insulin Compared to Technosphere Placebo in Patients With Type 2 Diabetes Mellitus Following Diabetes Education

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00511602
• Other study ID #: PDC-INS-0008
• Status: Completed
• Phase: Phase 2
• First received: August 3, 2007
• Last updated: April 27, 2012
• Start date: December 2003
• Est. completion date: December 2005

Study information

• Verified date: April 2012
• Source: Mannkind Corporation
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Primary objective to evaluate the effect of a 12-week treatment period with prandial administration of Technosphere Insulin on glucose control in subjects with T2 DM. Secondary objective is to Evaluate the safety and tolerability of a 12-week treatment period of Technosphere Insulin and Technosphere Placebo.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 123
• Est. completion date: December 2005
• Est. primary completion date: November 2004
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Clinical diagnosis of T2 DM of >2 years and <12 years duration

• Insulin treatment naive treated with diet/exercise or single/combination oral anti-diabetic agents, such as metformin, sulfonylurea, and/or thiazolidinediones

• Stable regimen for >3 months of oral anti-diabetes medication prior to enrollment

• HbA1c >6.6% and <10.5%

• BMI <38 kg/m2

• 18-80 years of age

• Baseline FVC and FEV1 >80% and <120% of predicted normal as measured by spirometry

• Baseline DLCO >80% and <120% of predicted normal

Exclusion Criteria:

• Clinical diagnosis of type 1 diabetes mellitus

• Subjects currently using insulin therapy or at the time of screening

• Known hypersensitivity to the study drug or to drugs of similar chemical structures

• Fasting plasma glucose >270 mg/dL without adequate explanation of a transient causality (screen could be repeated after a 2-week interim period)

• History of severe or multiple allergies

• History of tobacco or nicotine test at screening

• Severe complications of diabetes including history of blindness from or Stage III or IV diabetic retinopathy, history of renal failure requiring dialysis or transplantation, history of amputation of limbs or digits related to diabetic vasculopathy

• Treatment with another investigational drug within 3 months prior to study entry (and for the duration of the study)

• Use of medications known to modify glucose metabolism or to decrease the ability to recover from hypoglycemia such as oral, parenteral, and inhaled steroids, beta blockers, with the exception of beta blocker ophthalmic solutions for glaucoma or ocular hypertension, or hydrochlorothiazide (HCTZ) at doses >25 mg/day

• Recent loss (within the 2 months prior to screening) of >5% of body weight

• Evidence of moderate or greater ketones in urine or ketoacidosis at screening

• History of chronic obstructive pulmonary disease or history of other known chronic pulmonary disease such as reactive airway disease, chronic bronchitis, emphysema, or asthma

• Diagnosis of AIDS or ARC

• A major psychiatric disorder that would have precluded satisfactory participation in this study

• Subjects who had had a myocardial infarction or stroke within the preceding six months

• Prior diagnosis of systemic autoimmune or collagen vascular disease requiring heart disease graded as Class III or Class IV according to New York Heart Association criteria

• Prior treatment with, or participation in, a clinical study involving an inhaled insulin product

• History of malignancy within 5 years of study entry (other than basal cell carcinoma)

• Significant hepatic disease (as evidenced by ALT or AST >3 times the reference normal range or bilirubin >1.5 times the reference normal range)

• Significant renal disease (as evidenced by creatinine >1.5 mg/dL for males or >1.3 mg/dL for females), proteinuria as evidenced by greater than "small" by dipstick measurement or >2 grams in 24 hours, dialysis, or history of renal transplant

• History of previous or current treatment with systemic corticosteroids, cytotoxic drugs, or penicillamine

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 2 Diabetes Mellitus

Intervention

Drug:
• Technosphere Insulin
Technosphere Insulin Inhalation Powder
• Technosphere Placebo
Technosphere Inhalation Powder

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Mannkind Corporation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HbA1c change from baseline (week 2) to end of treatment (week 12)		12 weeks	No
Secondary	Area under the plasma glucose concentration versus time (AUCglucose)	Timepoints: 0, 30, 60, and 120 minutes after TI administration	every 4 weeks	No
Secondary	Maximum glucose concentration (Cmax)	Timepoints: 0, 30, 60, and 120 minutes after TI administration	every 4 weeks	No
Secondary	Time to maximum glucose concentration (tmax)	Timepoints: 0, 30, 60, and 120 minutes after TI administration	every 4 weeks	No
Secondary	Area under the plasma glucose concentration versus time (AUCglucose)	Timepoints: 0, 30, 60, and 120 minutes after Technosphere Placebo administration	every 4 weeks	No
Secondary	Maximum glucose concentration (Cmax)	Timepoints: 0, 30, 60, and 120 minutes after Technosphere Placebo administration	every 4 weeks	No
Secondary	Time to maximum glucose concentration (tmax)	Timepoints: 0, 30, 60, and 120 minutes after Technosphere Placebo administration	every 4 weeks	No
Secondary	Safety variables included adverse events (AEs), clinical laboratory tests, vital signs and physical examinations		every 2 weeks	No